查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492648

巨細胞病毒檢測市場：依測試類型、樣本類型、使用者群體、最終用途 – 2024-2030 年全球預測

Cytomegalovirus Tests Market by Test Type (Antigenemia Tests, Culture Tests, Molecular Tests), Sample Type (Blood Samples, Urine Samples), User Group, End Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

巨細胞病毒檢測市場規模預計2023年為6.4128億美元，2024年將達到6.8078億美元，預計2030年將達到10.2506億美元，複合年成長率為6.93%。

巨細胞病毒(CMV) 檢測是一種檢測個體體內是否有巨細胞病毒的醫學檢測。巨細胞病毒是皰疹病毒科中常見的病毒，可以感染所有年齡層的人。健康人即使被感染通常也不會表現出任何症狀，甚至可能沒有意識到自己被感染，但鉅細胞病毒對於免疫力較弱的人來說可能很嚴重，對於出生前感染的新生兒可能會造成嚴重的健康風險。社會和臨床對 CMV 影響的認知不斷提高，尤其是對孕婦和免疫力缺乏患者的影響，正在推動對 CMV 檢測的需求。此外，隨著全球器官移植數量的增加，對準確 CMV 檢測以確保移植安全和成功的需求也隨之增加。然而，高成本和獲得先進測試設施的機會有限可能會阻礙市場成長，特別是在新興市場。此外，各國複雜的監管環境和不同的報銷政策可能會成為採用先進 CMV 測試技術的障礙。此外，分子診斷的創新以及更快、更準確的測試方法的開拓也促進了市場的成長。利用次世代定序儀和基於 CRISPR 的技術進行 CMV 檢測有可能提高靈敏度、特異性和成本效益。

主要市場統計
基準年[2023] 64128萬美元
預計年份 [2024] 68078萬美元
預測年份 [2030] 1,025,060,000 美元
複合年成長率（%） 6.93%

區域洞察

美洲，特別是美國和加拿大，構成了巨細胞病毒（CMV）檢測的重要市場。醫療基礎設施的改善、醫療成本的上升以及人們對鉅細胞病毒感染疾病早期診斷和治療重要性的認知不斷提高，正在促進這些國家的市場成長。該地區消費者的需求是由對高標準醫療保健實踐和先進診斷解決方案的需求所驅動的。政府和私營部門支持的持續研究和開發工作旨在提高 CMV 測試的準確性和可及性。歐盟 (EU) CMV 檢測市場的特點是嚴格的監管標準以及病患照護和安全的重要原則。歐盟國家受益於完善的醫療保健系統和公民的高度健康意識。歐盟境內的消費者需要安全、經過驗證且具成本效益的測試選項。中東擁有阿拉伯聯合大公國和沙烏地阿拉伯等富裕國家，醫療保健產業不斷發展，對醫療保健基礎設施和服務的投資不斷增加。相反，非洲面臨醫療設施有限和缺乏意識等挑戰。由於醫療支出增加、經濟成長和龐大的患者數量，亞太地區正迅速崛起為重要的 CMV 檢測市場。中國和印度人口眾多，對負擔得起的醫療保健解決方案有很高的需求，包括鉅細胞病毒等感染疾病的診斷測試。日本以其先進的醫療保健系統和技術創新而聞名，表現出對高品質、精確診斷的偏好。這些國家的研究和開發舉措專注於創建滿足當地需求的具有成本效益和高效的診斷解決方案。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在巨細胞病毒測試市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對巨細胞病毒檢測市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對巨細胞病毒檢測市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地 CMV 感染盛行率上升
      • 提高公眾和臨床對 CMV 影響的認知
      • 全球肝臟移植數量不斷增加
    • 抑制因素
      • 成本高且先進測試設施的使用機會有限
    • 機會
      • 分子診斷創新和更快、更準確檢測方法的開發
      • 使用次世代定序和基於 CRISPR 的技術進行 CMV 檢測
    • 任務
      • 複雜的法規環境和特定國家的報銷政策
  • 市場區隔分析
    • 測試類型：在提高分子測試（尤其是聚合酵素鏈鎖反應）的靈敏度和特異性方面不斷取得進展
    • 最終用途：研究機構更多地使用巨細胞病毒檢測來開發疫苗
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章按測試類型分類的巨細胞病毒測試市場

  • 抗原血症測試
  • 文化測試
  • 分子檢測
  • 血清學檢測

第7章依樣本類型分類的巨細胞病毒檢測市場

  • 血液樣本
  • 尿液樣本

第8章按使用者群組分類的巨細胞病毒檢測市場

  • 免疫力缺乏者
  • 新生
  • 懷孕的女人

第9章巨細胞病毒檢測市場：依最終用途分類

  • 診斷實驗室
  • 醫院/診所
  • 調查機構

第10章美洲巨細胞病毒檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太鉅巨細胞病毒檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲巨細胞病毒檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准擴大使用默克公司的 PREVYMIS 來預防高風險腎移植患者的 CMV 感染
    • Diasolin 在先天性 CMV 檢測方面取得突破
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-6B0EA07975A5

[184 Pages Report] The Cytomegalovirus Tests Market size was estimated at USD 641.28 million in 2023 and expected to reach USD 680.78 million in 2024, at a CAGR 6.93% to reach USD 1,025.06 million by 2030.

Cytomegalovirus (CMV) tests are medical examinations used to detect the presence of the cytomegalovirus in an individual's body. The cytomegalovirus is a common virus that belongs to the herpesvirus family and can infect people of all ages. While healthy individuals often show no symptoms upon infection and may not be aware they have been infected, CMV can pose significant health risks to people with weakened immune systems and to newborns if they are infected before birth. Growing public and clinical awareness regarding the implications of CMV, especially in pregnant women and immunocompromised patients, drives the demand for CMV testing. Additionally, as the number of organ transplants increases globally, the need for precise CMV testing escalates to ensure safe and successful transplant outcomes. However, high costs and limited access to sophisticated testing facilities can impede market growth, particularly in developing regions. Moreover, complex regulatory landscapes and varying reimbursement policies across countries can create hurdles in the adoption of advanced CMV testing technologies. Furthermore, innovations in molecular diagnostics and the development of faster, more accurate testing methods contribute to market growth. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection offers the potential to improve sensitivity, specificity, and cost-effectiveness.

KEY MARKET STATISTICS
Base Year [2023] USD 641.28 million
Estimated Year [2024] USD 680.78 million
Forecast Year [2030] USD 1,025.06 million
CAGR (%) 6.93%

Regional Insights

The Americas, particularly the United States and Canada, represent a significant market for cytomegalovirus (CMV) tests. Enhanced healthcare infrastructure, high healthcare spending, and an increasing awareness of the significance of early diagnosis and treatment of CMV infections contribute to the market's growth in these countries. The consumer need in the region is driven by a high standard of healthcare practices and a demand for advanced diagnostic solutions. Ongoing research and development activities, supported by both government and private sectors, aim to improve the accuracy and accessibility of CMV testing. In the European Union, the market for CMV tests is characterized by stringent regulatory standards and a vital principle on patient care and safety. EU countries benefit from a well-established healthcare system and high health awareness among the population. The consumer need within the EU is for safe, validated, and cost-effective testing options. The Middle East, with its wealthier nations like the UAE and Saudi Arabia, is witnessing a growing healthcare sector with increasing investments in healthcare infrastructure and services. Conversely, Africa faces challenges such as restricted access to healthcare facilities and an insufficiency of awareness. The APAC region is rapidly emerging as a significant CMV test market driven by increasing healthcare expenditure, economic growth, and a huge patient population. China and India, with their vast populations, have a high demand for affordable healthcare solutions, including diagnostic tests for infectious diseases such as CMV. Japan, known for its advanced healthcare system and technological innovation, demonstrates a preference for high-quality and precision diagnostics. Research and development initiatives in these countries are focused on creating cost-effective and efficient diagnostic solutions to meet local needs.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cytomegalovirus Tests Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of CMV infections across the globe
      • Growing public and clinical awareness regarding the implications of CMV
      • Increasing number of liver transplant globally
    • Market Restraints
      • High cost and limited access to sophisticated testing facilities
    • Market Opportunities
      • Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • Market Challenges
      • Complex regulatory landscapes and varying reimbursement policies across countries
  • Market Segmentation Analysis
    • Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Tests Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Tests Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients

The U.S. Food and Drug Administration (FDA) has recently approved a new application for Merck's antiviral drug, Prevymis (letermovir), to include its use in preventing cytomegalovirus (CMV) disease among adult recipients of kidney transplants with high-risk. Prevymis aims to significantly reduce the risk of viral infection and associated complications by preventing the activation of the virus in patients with weakened immune systems post-transplant. This decision by the FDA was supported by robust clinical trials that demonstrated the drug's effectiveness and safety in this new patient demographic, paving the way for its broader use in transplant medicine. [Published On: 2023-06-06]

DiaSorin's Breakthrough in Congenital CMV Detection

DiaSorin, an Italian diagnostic firm, announced its achievement in gaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative Simplexa Congenital CMV Direct kit. This cutting-edge diagnostic tool marks a significant milestone as the first FDA-approved test to detect cytomegalovirus (CMV) DNA in both saliva and urine samples of newborns aged 21 days or younger. Integrating this test into the Liaison MDx instrument facilitates swift and accurate diagnoses of congenital CMV, enabling timely interventions and treatments. [Published On: 2022-11-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Tests Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Test Type
    • Antigenemia Tests
    • Culture Tests
    • Molecular Tests
    • Serological Tests
  • Sample Type
    • Blood Samples
    • Urine Samples
  • User Group
    • Immunocompromised Individuals
    • Newborns
    • Pregnant Women
  • End Use
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CMV infections across the globe
      • 5.1.1.2. Growing public and clinical awareness regarding the implications of CMV
      • 5.1.1.3. Increasing number of liver transplant globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited access to sophisticated testing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • 5.1.3.2. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes and varying reimbursement policies across countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • 5.2.2. End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cytomegalovirus Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Antigenemia Tests
  • 6.3. Culture Tests
  • 6.4. Molecular Tests
  • 6.5. Serological Tests

7. Cytomegalovirus Tests Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Samples
  • 7.3. Urine Samples

8. Cytomegalovirus Tests Market, by User Group

  • 8.1. Introduction
  • 8.2. Immunocompromised Individuals
  • 8.3. Newborns
  • 8.4. Pregnant Women

9. Cytomegalovirus Tests Market, by End Use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Cytomegalovirus Tests Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Tests Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Tests Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
    • 13.3.2. DiaSorin's Breakthrough in Congenital CMV Detection
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CYTOMEGALOVIRUS TESTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE,